| Nevada                                                                    |   |  27-4092986                              |
|---------------------------------------------------------------------------|--------|-----------------------------------------------|
|  (State or other jurisdiction of incorporation or organization) |   |  (I.R.S. Employer Identification Number) |

|  Large accelerated filer [ ] | Accelerated filer [ ] | Non-accelerated filer [ ](Do not check if a smaller reporting company) | Smaller reporting company [X] |
|----------------------------------------|-----------------------|------------------------------------------------------------------------|------------------------------------|

| AXIM BIOTECHNOLOGIES, INC.                                                                                                       |   |
|----------------------------------------------------------------------------------------------------------------------------------|--------|
|                                                                                                                             |   |
|                                                                                                                             | Page   |
|                                                                                                                             |   |
| Condensed Consolidated Balance Sheet as of  March 31, 2016 (unaudited) and December 31, 2015                           | F-2    |
|                                                                                                                             |   |
| Condensed Consolidated Statements of Operations for the three months ended March 31, 2016 and 2015 (unaudited):                  | F-3    |
|                                                                                                                             |   |
| Condensed Consolidated Statement of Changes in Shareholders' Deficit for the three months ended March 31, 2016 (unaudited). | F-4    |
|                                                                                                                             |   |
| Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2016 and 2015 (unaudited).                   | F-5    |
|                                                                                                                             |   |
| Notes to Condensed Consolidated Financial Statements (unaudited).                                                                | F-6    |
|                                                                                                                             |   |
| F-1                                                                                                                              |   |

----

| AXIM BIOTECHNOLOGIES, INC.                                                                                 |
|------------------------------------------------------------------------------------------------------------|
| (Formerly AXIM International, Inc.)                                                                        |
| Condensed Consolidated Balance Sheets                                                                      |
|                                                                                                       |   |   |   |   |   |   |
|                                                                                                       |   |   |   | March 31, |   | December 31, |
|                                                                                                       |   |   |   | 2016 |   | 2015 |
|                                                                                                       |   |   |   |   (unaudited) |   |   |
| ASSETS                                                                                                     |   |   |   |   |
|                                                                                                       |   |   |   |   |   |   |
| Current assets:                                                                                            |   |   |   |   |
|                                                                                                       | Cash | $ |             170,969 | $ | 134,170 |
|                                                                                                       | Inventory |   |             177,660 |   | 200,784 |
|                                                                                                       | Reservation fee deposit |   |              65,170 |   | 65,170 |
|                                                                                                       | Prepaid expenses |   |             158,109 |   | 777,657 |
|                                                                                                       | Loan receivable |   |                5,000 |   | 5,000 |
|                                                                                                       |   | Total current assets |   |             576,908 |   |           1,182,781 |
|                                                                                                       |   |   |   |   |   |   |
| Property & Equipment, net of accumulated depreciation of $1,958 and $1,119, respectively.              |              14,822 |   |               15,661 |
|                                                                                                       |   |   |   |   |   |   |
| Other Assets:                                                                                              |   |   |   |   |
|                                                                                                       | Acquired intangible asset - intellectual property licensing agreement, net |              63,167 |   |               63,167 |
|                                                                                                       |   | Total other assets |   |              63,167 |   |               63,167 |
|                                                                                                       |   |   |   |   |   |   |
| TOTAL ASSETS                                                                                               | $ | 654,897 | $ | 1,261,609 |
|                                                                                                       |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS'  DEFICIT                                                           |   |   |   |   |
|                                                                                                       |   |   |   |   |   |   |
| Current liabilities:                                                                                       |   |   |   |   |
|                                                                                                       | Accounts payable and accrued liabilities | $ |             455,105 | $ | 392,937 |
|                                                                                                       | Due to shareholder |   |                5,000 |   | 5,000 |
|                                                                                                       | Convertible loan |   |              50,000 |   | 50,000 |
|                                                                                                       | Due to first insurance funding |   |                7,688 |   | 22,964 |
|                                                                                                       | Due to related party |   |          1,315,910 |   | 1,085,910 |
|                                                                                                       | Promissory note - related party |   |          1,000,000 |   | 1,000,000 |
|                                                                                                       |   | Total current liabilities |   | 2,833,703 |   | 2,556,811 |
|                                                                                                       |   |   |   |   |   |   |
| Long-term liabilities:                                                                                     |   |   |   |   |
|                                                                                                       | Convertible note payable |   |             400,000 |   |              400,000 |
|                                                                                                       |   | Total long-term liabilities |   |             400,000 |   |              400,000 |
|                                                                                                       |   |   |   |   |   |   |
| TOTAL LIABILITIES                                                                                          |   | 3,233,703 |   | 2,956,811 |
|                                                                                                       |   |   |   |   |   |   |
| STOCKHOLDERS'  DEFICIT                                                                           |   |   |   |   |
|                                                                                                       | Preferred stock, $0.0001 par value, 5,000,000 shares authorized; |   |   |   |   |
|                                                                                                       |   | Series A Convertible Preferred stock, $0.0001 par value, 1,000,000 shares |   |   |
|                                                                                                       |   | designated, 1,000,000 shares issued and outstanding; respectively |                   100 |   |                    100 |
|                                                                                                       |   | Undesignated Preferred stock, $0.0001 par value, 4,000,000 shares authorized, |   |
|                                                                                                       |   | 1,000,000 shares issued and outstanding |   |                   100 |   | 100 |
|                                                                                                       | Common stock, $0.0001 par value, 300,000,000 shares authorized |   |   |   |
|                                                                                                       |   | 39,762,659 and 39,633,706 shares issued and outstanding, respectively; |                3,976 |   | 3,963 |
|                                                                                                       | Additional paid in capital |   |          9,088,475 |   | 9,032,865 |
|                                                                                                       | Common stock to be issued |   |              67,375 |   |               52,500 |
|                                                                                                       | Accumulated deficit |   |       (11,738,832) |   | (10,784,730) |
|                                                                                                       |   |   |   |   |   |   |
| TOTAL STOCKHOLDERS'  DEFICIT                                                                     |   |         (2,578,806) |   | (1,695,202) |
|                                                                                                       |   |   |   |   |   |   |
| TOTAL LIABILITIES AND STOCKHOLDERS'  DEFICIT                                                     | $ |             654,897 | $ | 1,261,609 |
|                                                                                                       |   |   |   |   |   |   |
|                                                                                                       |   |   |   |   |   |   |
| The accompanying notes are an integral part of these unaudited condensed consolidated financial statements |
| F-2                                                                                                        |

----

| AXIM BIOTECHNOLOGIES, INC.                                                                                 |
|------------------------------------------------------------------------------------------------------------|
| (Formerly AXIM International, Inc.)                                                                        |
| Condensed Consolidated Statement of Operations                                                             |
|  (unaudited)                                                                                          |
|                                                                                                       |   |   |   |   |   |
|                                                                                                       |   |   | For the |   | For the |
|                                                                                                       |   |   |            Three Months ended | Three Months ended |
|                                                                                                       |   |   | March 31, 2016 |   | March 31, 2015 |
|                                                                                                       |   |   |   |   |   |
| Revenues                                                                                                   |   | $ |                   14,005 | $ |                           - |
|                                                                                                       |   |   |   |   |   |
| Cost of goods sold                                                                                         |   |   |                   15,214 |   |                           - |
|                                                                                                       |   |   |   |   |   |
| Gross loss                                                                                                 |   |   |                   (1,209) |   |                           - |
|                                                                                                       |   |   |   |   |   |
| Expenses:                                                                                                  |   |   |   |   |   |
|                                                                                                       |   |   |   |   |   |
| Research and development expenses                                                                          |   |                   31,180 |   |                    62,669 |
| Selling, General and administrative                                                                        |   |                 908,952 |   |                  426,149 |
| Depreciation                                                                                               |   |   |                       839 |   |                           - |
|                                                                                                       |   |   |   |   |   |
| Total operating expenses                                                                                   |   |   |                 940,971 |   |                  488,818 |
|                                                                                                       |   |   |   |   |   |
| Loss from operations                                                                                       |   |   |                (942,180) |   |                 (488,818) |
|                                                                                                       |   |   |   |   |   |
| Other (Income) expenses:                                                                                   |   |   |   |   |   |
|      Interest expense                                                             |   |   |                   11,922 |   |                    18,128 |
|                                                                                                       |   |   |                   11,922 |   |                    18,128 |
|                                                                                                       |   |   |   |   |   |
| Loss before provision of income tax                                                                        |   |                (954,102) |   |                 (506,946) |
| Provision for income tax                                                                                   |   |   |                         - |   |                           - |
|                                                                                                       |   |   |   |   |   |
|                                                                                                       |   |   |   |   |   |
| NET LOSS                                                                                                   |   | $ |                (954,102) | $ |                 (506,946) |
|                                                                                                       |   |   |   |   |   |
| Loss per common share - basic and diluted                                                                  | $ |                     (0.02) | $ |                      (0.02) |
|                                                                                                       |   |   |   |   |   |
| Weighted average common shares outstanding - basic and diluted                                             |   | 39,709,864 |   | 33,018,000 |
|                                                                                                       |   |   |   |   |   |
| The accompanying notes are an integral part of these unaudited condensed consolidated financial statements |
| F-3                                                                                                        |

----

| AXIM BIOTECHNOLOGIES, INC.                                                                                 |
|------------------------------------------------------------------------------------------------------------|
| (Formerly AXIM International, Inc.)                                                                        |
|       Condensed Consolidated Statement of Stockholders' Deficit              |
| For the three months ended March 31, 2016                                                                  |
|  (unaudited)                                                                                          |
|                                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                                                       |   |   |   |   |   |   |   |   |   | Series A Convertible |   |   |   |   |   |   |
|                                                                                                       | Common Stock |   | Preferred Stock |   |   | Preferred Stock | Common Stock | Additional |   | Accumulated |   |
|                                                                                                       | Shares |   | Amount | Shares |   | Amount | Shares |   | Amount | to be Issued |   | Paid In Capital |  Deficit |   | Total |
| Balance at December 31, 2015                                                                               | 39,633,706 |  $ | 3,963 |   | 1,000,000 |  $ | 100 |   | 1,000,000 |  $ |       100 |  $ |              52,500 |  $ | 9,032,865 |  $ | (10,784,730) |  $ | (1,695,202) |
|                                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Common stock to be issued for officer's compensation                                                       |       125,000 |   |        13 |   |              - |   |         - |   |              - |   |         - |   |             (52,500) |   |            52,487 |   |                  - |   |                - |
|                                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Common stock to be issued for officer's compensation                                                       |               - |   |         - |   |              - |   |         - |   |              - |   |         - |   |              67,375 |   |                   - |   |                  - |   |         67,375 |
|                                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Common stock issued for consulting services                                                                |          3,953 |   |         - |   |   |   |   |   |   |   |   |   |   |   |              3,123 |   |   |   |           3,123 |
|                                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net Loss                                                                                                   |               - |   |         - |   |              - |   |         - |   |              - |   |         - |   |                     - |   |                   - |   | (954,102) |   | (954,102) |
|                                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance at March 31, 2016                                                                                  | 39,762,659 |  $ | 3,976 |   | 1,000,000 |  $ | 100 |   | 1,000,000 |  $ |       100 |  $ |              67,375 |  $ | 9,088,475 |  $ |    (11,738,832) |  $ |    (2,578,806) |
|                                                                                                       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| The accompanying notes are an integral part of these unaudited condensed consolidated financial statements |
| F-4                                                                                                        |

----

| AXIM BIOTECHNOLOGIES, INC.                                                                                 |
|------------------------------------------------------------------------------------------------------------|
| (Formerly AXIM International, Inc.)                                                                        |
| Condensed Consolidated Statements of Cash Flows                                                            |
| (unaudited)                                                                                                |
|                                                                                                       |   |   |   |   |   |
|                                                                                                       |   |   |   |   |   |
|                                                                                                       |   |   | For the |   | For the |
|                                                                                                       |   |   | Three Months ended | Three Months ended |
|                                                                                                       |   |   | March 31, 2016 |   | March 31, 2015 |
| CASH FLOWS FROM OPERATING ACTIVITIES:                                                                      |   |   |   |   |
|                                                                                                       | Net loss | $ |                      (954,102) | $ | (506,946) |
|                                                                                                       |   |   |   |   |   |
|                                                                                                       | Loss from operations |   |                      (954,102) |   | (506,946) |
|                                                                                                       |   |   |   |   |   |
|                                                                                                       |   |   |   |   |   |
|                                                                                                       | Adjustments to reconcile net loss to net cash used in operating activities: |   |   |
|                                                                                                       | Expenses incurred by related party on behalf of the Company, net |                                    - |   | (29,011) |
|                                                                                                       | Depreciation expense |   |                                839 |   |                                    - |
|                                                                                                       | Amortization of prepaid services |   |                        598,356 |   |                                    - |
|                                                                                                       | Amortization of prepaid insurance |   |                          21,192 |   |                           36,986 |
|                                                                                                       | Stock based compensation |   |                          70,498 |   |                           36,000 |
|                                                                                                       | Inventory written off |   |                             9,659 |   |                                    - |
|                                                                                                       |   |   |   |   |   |
|                                                                                                       | Change in operating assets and liabilities: |   |   |   |   |
|                                                                                                       | Accounts payable and accrued expenses |   |                          62,168 |   |                           37,507 |
|                                                                                                       | Inventory |   |                          13,465 |   |                                    - |
|                                                                                                       | Due to first insurance funding |   |                         (15,276) |   |                         (40,410) |
|                                                                                                       |   |   |   |   |   |
| NET CASH USED IN OPERATING ACTIVITIES                                                                      |   |                      (193,201) |   |                       (465,874) |
|                                                                                                       |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:                                                                      |   |                                    - |   |                                    - |
|                                                                                                       |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:                                                                      |   |   |   |   |
|                                                                                                       | Proceeds from due to related party |   |                        230,000 |   |                                    - |
|                                                                                                       |   |   |   |   |   |
| NET CASH PROVIDED BY  FINANCING ACTIVITIES                                                       |   |                        230,000 |   |                                    - |
|                                                                                                       |   |   |   |   |   |
| NET CHANGE IN CASH                                                                                         |   |                          36,799 |   |                       (465,874) |
| CASH BALANCES                                                                                              |   |   |   |   |
|                                                                                                       |   Beginning of  period |   | 134,170 |   | 661,128 |
|                                                                                                       |   End of  period | $ | 170,969 | $ |                         195,254 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:                                                          |   |   |
|      CASH PAID DURING THE PERIOD FOR:                                             |   |   |   |   |
|                                                                                                       |   Interest | $ |                                179 | $ |                                    - |
|                                                                                                       |   Income taxes-net of tax refund | $ |                                    - | $ |                                    - |
|                                                                                                       |   |   |   |   |   |
| SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING TRANSACTIONS:                                    |
|                                                                                                       | Common stock issued against CS to be issued | $ |                          52,500 |   |                                    - |
|                                                                                                       |   |   |   |   |   |
| The accompanying notes are an integral part of these unaudited condensed consolidated financial statements |
| F-5                                                                                                        |

----

|                       |   | March 31, 2016  |   | December 31, 2015 |
|----------------------------|--------|----------------------|--------|-------------------|
| Prepaid service contract   | $      |  138,082        | $      | 736,438           |
| Prepaid insurance contract |   | 20,027               |   | 41,219            |
|                       | $      | 158,109              | $      | 777,657           |

|                                                                         |   | March  31,2016 |   | December 31,2015 |
|------------------------------------------------------------------------------|--------|--------------------------|--------|------------------|
| Promissory note payable, due on demand, interest at 3% and 7%, respectively. | $      |  1,000,000          | $      | 1,000,000        |
| Accrued interest                                                             |   | 65,343                   |   | 57,726           |
|                                                                         | $      | 1,065,343                | $      | 1,057,726        |

----

| - | Completing a clinical trial at the Free University of Amsterdam, The Netherlands in collaboration with the University of Plymouth, UK as well as academic center in the USA for a novel, patented delivery form of cannabinoids for treatment of chronic pain and spasticity in patients with multiple sclerosis.   The anticipated duration of the trials prior to FDA/ EMA registration is 24 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| - | Conducting research trials of a novel delivery mechanism (patent pending) for treatment of patients with ADHD. Conducting of clinical trials at the university of Wageningen, The Netherlands on patients with irritable bowel syndrome, inflammatory bowel disease, ulcerative colitis  and Crohn’s disease using innovative, (patent pending) delivery mechanisms containing cannabinoids. Conducting of a clinical trial at the University of British Columbia, Canada on patients suffering of drug-related psychosis using innovative, (patented) delivery mechanisms containing cannabinoids. Conducting of a clinical trial at the  Dermatological center Maurits clinic  The Hague, The Netherlands on patients with psoriasis and atopic dermatitis using innovative, (patent pending) delivery mechanisms containing cannabinoids.  |
| - | Development of novel (patent pending) pharmaceutical and nutriceutical cannabinoid-based preparation “CannQuitTM” formulations for smoking cessation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| - | Conducting of clinical trials at the university of Wageningen, The Netherlands on patients with irritable bowel syndrome, inflammatory bowel disease and Crohn’s disease using innovative, (patent pending) delivery mechanisms.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| - | New (patent pending) cannabinoid extraction technologies in The Netherlands.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| - | Development of our 95% pure, freeze-dried cannabinoids products (patent pending).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| - | Development of high-energy-output hemp coal “CannaCoalTM.” (patent pending).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| - | Development of novel (patent pending) antibacterial preparations based on cannabinoids.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| - | Development and commercialization of oral healthcare products, “OraximaxTM”, based on cannabigerol (patent pending).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| - | Development and commercialization of cosmetic care line “RenecannTM” (patent pending).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| - | Development of ophtalmological preparations based on cannabigerol “CannBlephTM” (patent pending). Development of new active pharmaceutical ingredient molecules including, prodrug formulations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| - | Completion of a land purchase in the city of Almere, in the province of Flevoland, The Netherlands for building of a state of the art extraction/ purification  facility as well as a factory for pharmaceutical, nutriceutical and consumer products preparations as well as an innovative, environmentally-friendly; “box in a box”-design center for R&D and manufacturing..                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| - | Importation from Italy, Spain, Denmark, the Netherlands and other reputable producers of pharmaceutical grade hemp oil to Europe and North America. Some of these products will be converted by AXIM from lipophilic to hydrophilic form based on proprietary process (patent pending).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| - | Development of sustainable biofuel compositions derived from industrial hemp by-products.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

|                              | Three MonthsPeriod EndedMarch 31, 2016 |   | Three MonthsPeriod EndedMarch 31, 2015 |
|-----------------------------------|----------------------------------------|--------|----------------------------------------|
|                              |                                   |   |                                   |
| Legal and other fees              | $52,569                                |   | $41,396                                |
| Depreciation                      | 839                                    |   | -                                      |
| Audit fees                        | -                                      |   | 2,500                                  |
| Filing fees                       | 155                                    |   | 679                                    |
| Office/Other expenses             | 4,422                                  |   | 5,573                                  |
| Interest expense                  | 11,922                                 |   | 18,128                                 |
|                              |                                   |   |                                   |
| Travel and entertainment expenses | 3,504                                  |   | 35,088                                 |
| Advertising and promotions        | 31,120                                 |   | 62,544                                 |
| Compensation costs                | 665,731                                |   | 36,000                                 |
| Insurance expense                 | 21,192                                 |   | 37,531                                 |
| Impairment                        | 9,659                                  |   | -                                      |
| Consulting fees                   | 41,392                                 |   | 111,611                                |
|                              |                                   |   |                                   |
| Taxes                             | 5,197                                  |   | 5,910                                  |
| Officer’s salary            | 60,000                                 |   | 60,000                                 |
| Research and development          | 31,180                                 |   | 62,669                                 |
| Licenses and permits              | 14,011                                 |   | 27,317                                 |
| Total                             | $952,893                               |   | $506,946                               |

----

| Statements                                                                                                                                   |   |   |   |   |
|----------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|
|                                                                                                                                         |   |   |   |   |
| Condensed Consolidated Balance Sheets as of March 31, 2016 (unaudited) and December 31, 2015.                                                |
|                                                                                                                                         |   |   |   |   |
| Condensed Consolidated Statements of Operations for the three months ended March 31, 2016 and 2015 (unaudited)                               |
|                                                                                                                                         |   |   |   |   |
| Condensed Consolidated Statements of Changes in Shareholders' Deficit for the three months ended March 31, 2016 (unaudited)                  |
|                                                                                                                                         |   |   |   |   |
| Condensed Consolidated Statements of Cash Flows for the three months  ended March 31, 2016 and 2015 (unaudited)                    |
|                                                                                                                                         |   |   |   |   |
| Notes to Condensed Consolidated Financial Statements (unaudited)                                                                             |   |   |   |   |
|                                                                                                                                         |   |   |   |   |
| Schedules                                                                                                                                    |   |   |   |   |
|                                                                                                                                         |   |   |   |   |
| All schedules are omitted because they are not applicable or the required information is shown in the Financial Statements or notes thereto. |
|                                                                                                                                         |   |   |   |   |

|                                                                                                                                                           | Exhibit | Incorporated by Reference | Filing     | Filed with  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|---------------------------|------------|-------------|
| Exhibits                                                                                                                                                       | #       | (Form Type)               | Date       | This Report |
|                                                                                                                                                           |    |                      |       |        |
| Articles of Incorporation, as filed with the Nevada Secretary of State on November 18, 2010.                                                                   | 3.1     | 10-Q                      | 11/14/2014 |        |
|                                                                                                                                                           |    |                      |       |        |
| By-laws.                                                                                                                                                       | 3.2     | 10-Q                      | 11/14/2014 |        |
|                                                                                                                                                           |    |                      |       |        |
| Certificate of Amendment, as filed with the Nevada Secretary of State on July 24, 2014.                                                                   | 3.3     | 10-Q                      | 11/14/2014 |        |
|                                                                                                                                                           |    |                      |       |        |
| Employment Agreement effective June 13, 2014, by and between the Company and Dr. George E. Anastassov.                                                    | 10.1    | 10-K                      | 4/14/2015  |        |
|                                                                                                                                                           |    |                      |       |        |
| Employment Agreement effective January 1, 2016, by and between the Company and Lekhram Changoer.                                                               | 10.2    |                      |       |  X     |
|                                                                                                                                                           |    |                      |       |        |
| Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended | 31.1    |                      |       | X           |
|                                                                                                                                                           |    |                      |       |        |
| Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as amended | 31.2    |                      |       | X           |
|                                                                                                                                                           |    |                      |       |        |
| XBRL Instance Document                                                                                                                                         | 101.INS |                      |       | X           |
|                                                                                                                                                           |    |                      |       |        |
| XBRL Taxonomy Extension Schema Document                                                                                                                        | 101.SCH |                      |       | X           |
|                                                                                                                                                           |    |                      |       |        |
| XBRL Taxonomy Extension Calculation Linkbase Document                                                                                                          | 101.CAL |                      |       | X           |
|                                                                                                                                                           |    |                      |       |        |
| XBRL Taxonomy Extension Definition Linkbase Document                                                                                                           | 101.DEF |                      |       | X           |
|                                                                                                                                                           |    |                      |       |        |
| XBRL Taxonomy Extension Label Linkbase Document                                                                                                                | 101.LAB |                      |       | X           |
|                                                                                                                                                           |    |                      |       |        |
| XBRL Taxonomy Extension Presentation Linkbase Document                                                                                                         | 101.PRE |                      |       | X           |

----

|                           | AXIM BIOTECHNOLOGIES, INC. |
|--------------------------------|----------------------------|
|                           |                       |   |
| Dated:  May 23, 2016 | By:                        | /s/ Dr. George Anastassov |
|                           |                       | Dr. George Anastassov |
|                           |                       | President and DirectorPrincipal Executive OfficerPrincipal Financial Officer |